Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Well, Zacks still considers Bohai a strong buy for whatever that's worth.
http://www.zacks.com/stock/quote/BOPH
It's probably tanking due to the fact that I bought it. lol
Current report filing (8-K)
Date of Report (Date of Earliest Event Reported): December 8 , 2011
Bohai Pharmaceuticals Group, Inc.
c/o Yantai Bohai Pharmaceuticals Group Co. Ltd.
No. 9 Daxin Road, Zhifu District
Yantai, Shandong Province, China 264000
(Address of principal executive offices)
Registrant’s telephone number, including area code: +86(535)-685-7928
Item 8.01 Other Information
On January 5, 2010, Bohai Pharmaceuticals Group, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ SPA ”) with certain accredited investors (the “ Investors ”), for which Euro Pacific Capital, Inc. (“ Euro Pacific ”) is acting as representative, whereby the Company issued two-year convertible notes in the aggregate amount of $12 million (collectively, the “ Notes ”) and warrants to purchase shares of the Company’s common stock. As of the date of this Report, there is currently $10.5 million due under the Notes and the current maturity date of the Notes is January 5, 2012.
The Company is currently working with Euro Pacific as representative of the Investors on an amendment to the Notes (the “ Proposed Amendment ”) which would: (i) extend the maturity date of the Notes from January 5, 2012 to April 5, 2012 (such extra three month period, the “ Extended Period ”); and (ii) increase the interest rate on the Notes to an annual rate of 12% (or 3% for the Extended Period). Under the terms of the SPA, Euro Pacific has the power and authority to enter into the Proposed Amendment on behalf of the Investors and will undertake a process during the month of December 2011 of informing the Investors of the Proposed Amendment, following which (and prior to the original maturity date of the Notes) it is expected that the Company and Euro Pacific will formally enter into the Proposed Amendment.
This stock sure is a sleeper. I'm surprised that Zacks hasn't written anything on them lately. They would get some attention if they started giving a divy.
Bohai Pharmaceuticals Group Reports 78.3% Increase in Revenue for the Fiscal First Quarter of 2012
http://ih.advfn.com/p.php?pid=nmona&article=49929258&symbol=BOPH
Any thoughts on the house cleaning of management?
Ener1 Announces Changes to Senior Management Team to Aid in Continued Business Transformation
Alex Sorokin and Dale Parker Join Company as Interim CEO & Interim CFO, respectively; Nicholas Brunero Steps into Interim President Role
Former CEO and CFO to Consult with Company through Transition
NEW YORK, Nov. 7, 2011 /PRNewswire/ -- Ener1, Inc. (OTC:HEVV.ob - News) today announced that Alex Sorokin has joined the company as interim chief executive officer to lead the company's continuing efforts to improve its performance and shift its business toward heavy-duty transportation and electric grid energy storage applications. Nicholas Brunero, who has served as Ener1's general counsel since 2008, has accepted the additional role of interim president. In addition, Dale E. Parker, a seasoned financial executive and currently chairman of the board of HickoryTech Corporation (NASDAQ:HTCO - News), will serve as interim chief financial officer.
Both Chris Cowger, who most recently served as chief executive officer, and Jeffrey Seidel who served as chief financial officer, have resigned from the company. Messrs. Cowger and Seidel will remain available to management under new consulting agreements to ensure a smooth transition and assist in the company's transformation efforts.
"Alex and Dale bring a strong combination of operational and financial expertise with companies that are undergoing change," said Thomas J. Snyder, non-executive chairman of the board, Ener1, Inc. "Together with Nick Brunero, who has been a part of nearly every facet of our business over the last three-and-a-half years, they will sharpen our focus on how we leverage Ener1's energy storage expertise, while implementing a sustainable structure to support our go-forward business strategy. We want to thank Chris and Jeff for their service to the company, and for their commitment to its potential, and we're pleased that they will continue to work with us to position the company for the future."
Mr. Sorokin brings nearly thirty years of experience successfully leading companies through periods of transition and transformation. Prior to joining Ener1, he has assisted more than 30 companies in restructuring and improving their businesses in the U.S. and internationally across a range of industries including technology, transportation and heavy manufacturing. He is a graduate of Johns Hopkins University.
Mr. Brunero has served as vice president, general counsel and corporate secretary of Ener1 since January 2010. He was previously the company's vice president and deputy general counsel from March 2008 to December 2009. Prior to joining the company, Mr. Brunero was an attorney at the law firm of Duval & Stachenfeld LLP, where his practice focused primarily on the representation of financial institutions in connection with commercial litigations. He received his bachelor's degree from Bates College and his J.D. degree from Brooklyn Law School. He will retain his general counsel responsibilities, in addition to his new role as interim president.
In addition to his role as chairman of the board of HickoryTech, Mr. Parker served in senior financial positions for industrial companies, including as CFO of Neenah Industries, PaperWorks Industries, Forest Resources and Appleton Papers. From 1975 to 2000, he held financial positions of increasing responsibility at Black Clawson Companies, a manufacturer of capital equipment for the paper and plastics industries. He received his MBA from Xavier University and his bachelor's degree from Miami University in Ohio. Mr. Parker is also a Certified Public Accountant.
2morrows, great DD as usual. Thanks for your continued contributions!
Good article, thanks. eom
This situation is unbelievable for a company of this stature. Lemonade stands are better managed.
Yes, with such little OS once this baby gets recognized it could really move. I would like to add some more into my account before that happens though. : )
Time to get real? Time for you to take a chill pill.
If you think I'm touting this pos stock you better spend a few hours reading my previous post #20571.
As for the SEC, years ago they were begged to come in and investigate pwtc by a new CEO the company had after a previous one stepped down. Result nada. The SEC has had many opportunities since then to check on pwtc. Same result.
IF, and that's a big IF and when the SEC gets here, even with this new scam, they are already too late to the party.
Pink sheet and OTC stocks have the reputation they do because of the lack of enforcement from the SEC.
It's nice to hear the SEC may be getting off their butts. I would still bet that they will show up to the party here late. : )
Seeing as how the young person has so little capital to work with, he really needs his fifty back.
I guess the question is which comes here first, .0003 or the SEC?
I have little confidence in either but even less so in the SEC. lol
moneystocks: Unless you are constrained by time, I would put in a GTC sell order at .0003 for two reasons. First, if you just hang on to the stock instead of selling it at a loss, you at least don't lose additional money from the brokerage fee for selling it.
Secondly, it's not likely the SEC will ever intercede into the stock. The SEC is pretty much worthless in their enforcement activities. And who knows, maybe with time you may get your investment back.
Bohai Reports Significant Top Line And Bottom Line Increase For Fiscal 2011
Zacks Equity Research, On Friday September 30, 2011, 10:10 am
Grant Zeng, CFA
On September 29, 2011, Bohai Pharmaceutical Group Inc. (BOPH) reported financial results for the twelve months ended June 30, 2011.
Revenue for the fiscal year ended June 30, 2011 increased 37.2% to $81.3 million as compared to $59.3 million for the fiscal year ended June 30, 2010. This increase was primarily due to a 28.3% increase in the Company's four lead products (Lung Nourishing Syrup, Tongbi Capsules, Tongbi Tablets and Shantongning Tablets), which accounted for over 76% of total revenues.
Gross profit for the fiscal year ended June 30, 2011 was $64.0 million, compared to $49.1 million for the same period last year. Gross profit margin as a percentage of revenue declined to 78.7% from 82.8% for the same period last year. The decrease in gross profit margin was principally due to lower gross profit margins from five products introduced in May of 2010 due to higher manufacturing costs and lower unit sales prices. Excluding gross profit from the five new products, total gross profit margin would have been 81.9%, in line with gross profit margin of 82.8% for the twelve months ended June 30, 2010.
Selling, general and administrative expenses increased 26.3% to 445.8 million due to increased marketing and promotion expenses related to the Company's lead products.
Operating income for the twelve months ended June 30, 2011 increased 42.1% to $18.3 million compared to $12.8 million for the twelve months ended June 30, 2010.
GAAP Net income for the twelve months ended June 30, 2011 was $14.0 million or $0.75 per diluted share, compared to $9.1 million or $0.55 per diluted share, for the twelve months ended June 30, 2010. The increase in net income for the twelve months ended June 30, 2011 over the same period last year was primarily attributable to an increase in total gross profit of $14.9 million offset by an increase in selling, general and administrative expenses of $9.5 million and an increase in the tax provision of $1.4 million this fiscal year compared to the same period in 2010.
On an adjusted basis, Non-GAAP net income increased 37.4% to $11.8 million or $0.66 per diluted share versus $8.6 million or $0.52 per diluted share in fiscal 2010.
Total other income included a non-cash gain for change in fair value of investor and placement agent warrants of $4.5 million for the twelve months ended June 30, 2011 compared to $0.9 million for the same period in 2010. Total other income for the twelve months ended June 30, 2011 was also comprised of non-cash interest expenses for the unamortized discount of the convertible notes converted in connection with the Company's private placement on January 5, 2010 and non-cash charges for deferred tax expense of $0.4 million.
At June 30, 2011, Bohai had cash and cash equivalents of $13.3 million and restricted cash of $11,043.
Our key takeaways from the financial report include:
• Bohai continued its growth momentum in the current fiscal year;
• Both total revenue and net income exceeded our estimates ($81.3 million vs $80.8 million for revenue and $0.66 vs $0.52 for EPS);
• Through the acquisition of Yantai TianZheng, revenue base is further diversified and company size increased dramatically;
• Both top line and bottom line will continue to grow dramatically in the next 5 years due the acquisition of Yantai Tianzheng;
• Balance sheet is very strong with $13.3 million in cash and no long term debt as of June 30, 2011.
We have an Outperform rating on Bohai with a price target of $8 per share.
Zacks Investment Research
Good to see you here too Otterman. eom
Hi logman, you seem familiar to me. lol BOPH seems promising but they could use some exposure. If they payed out some kind of dividend that would garner some attention.
Yes, nice work 2morrowsGains. eom
Form 10-K for BOHAI PHARMACEUTICALS GROUP, INC.
28-Sep-2011
Annual Report
http://biz.yahoo.com/e/110928/boph.ob10-k.html
Looking forward to working with you.
Your welcome to be assistant mod if you like.
Gotcha : )
It's been on my watch list for sometime but I just recently took up a small position in it.
Yes, unlike some China based companies, this one appears to be legit. Welcome here Ernie.
Bohai Pharmaceuticals Appoints Marcum Bernstein & Pinchuk LLP as Independent Registered Public Accounting Firm
NEW YORK and YANTAI, China, July 1, 2011 (GLOBE NEWSWIRE) -- Bohai Pharmaceuticals Group, Inc. (OTCBB:BOPH) a China-based pharmaceutical company engaged in the production, manufacturing and distribution of modernized traditional Chinese medicine (TCM) in China, today announced that the audit committee of the company's board of directors has appointed Marcum Bernstein & Pinchuk LLP as the company's new independent registered public accounting firm.
Mr. Hongwei Qu, Chairman, President and CEO of Bohai Pharmaceuticals, stated, "Given the rapid growth in our business, we decided for the benefit of our company and our shareholders to engage one of the largest independent accounting firms in the U.S. Marcum has a strong global reputation and extensive expertise and physical presence in the China market, which we believe reinforces our commitment to the highest levels of transparency and strong corporate governance."
http://finance.yahoo.com/news/Bohai-Pharmaceuticals-pz-2606696434.html?x=0&.v=1
Why should investors pay attention to Bohai?
Zack's Investment Research
May 03, 2011
BOPH
Grant Zeng, CFA
Why should investors pay attention to Bohai?
Bohai Pharmaceuticals Group adds 200 hospitals and 10 new drug store chains to its national distribution network for Lung Nourishing Syrup
On April 25, 2011, Bohai Pharmaceuticals Group (BOPH - Analyst Report), announced that during the fiscal third quarter of 2011 ending March 31, 2011, the company added 200 level 2 hospitals and10 new drug store chains to its national network of retail locations in China currently selling the company's Lung Nourishing Syrup. As a result, the Company now sells Lung Nourishing Syrup in approximately 1,600 level 2 hospitals and 36 drug store chains across China.
As a reminder, Lung Nourishing Syrup, one of Bohai's leading products, is a novel formulation of a liquid product similar to cough syrup that is swallowed. Bohai holds a patent on Lung Nourishing Syrup for the treatment of Lung Qi Deficiency Cough and Chronic Bronchitis, which was approved by the State Intellectual Property Office of the PRC on June 23, 2010. The patent was awarded for a period of 20 years starting from the day of its application on September 12, 2007. In addition, Lung Nourishing Syrup, together with two other of Bohai's lead products, Tongbi Capsules and Tongbi Tablets, are eligible for reimbursement under China's National Medical Insurance Program, which enhances the marketability of the product.
It’s our belief that strong demand for Lung Nourishing Syrup will continue due to increasing concerns about respiratory and lung health caused by pervasive national air pollution in China.
Bohai’s goal is to target 600 hospitals in 100 locations throughout China for direct marketing of its products. We have seen that these efforts have begun to show positive results with the strong adoption by hospitals and national drug stores of Bohai’s Lung Nourishing Syrup, along with other key TCM products.
What are the implications of this sales network expansion for Bohai?
Lung Nourishing Syrup is Bohai’s top selling product. In fiscal year 2010 ended June 2010, Lung Nourishing Syrup generated sales of $15.5 million, accounting for 26.2% of total revenue of $59.3 million. In the first and second quarter of fiscal 2011 ended September and December 2010, sales from Lung Nourishing Syrup were $4.7 and $5.7 million respectively, accounting for 27.7% and 25.7% of total revenue respectively.
We expect sales from Lung Nourishing Syrup will increase by 35% in the fiscal year of 2011 ending June 30, 2011. As the Company approaches the date to report its third quarter financials and operations, we have reasons to expect a strong third quarter financial performance from Bohai. We estimate Bohai’s total revenue will reach $21.1 million, an increase of 40% over the same period of last year. EPS will reach $0.15, an increase one cent over $0.14 for the same period of last year. For the fiscal year of 2011 ending June 30, 2011, total revenue will reach $79.9 million, a 35% increase compared to $59.3 million in the fiscal year of 2010. EPS for 2011 will be $0.56 compared to $0.45 for fiscal year of 2010.
Why should investors pay attention to Bohai?
For investors who are new to Bohai, here is the background of the Company. Bohai is a well-established specialty pharmaceutical company in China engaged in the production and commercialization of traditional Chinese medicine (TCM). The Company is operating in a favorable environment for the pharmaceutical, especially TCM, industry in China. China’s GDP will continue to grow at about 8% in the coming decade. Government spending in healthcare will also increase dramatically. China’s goal to achieve a universal health insurance is on track with at least 90% of population is covered by 2011. Government supports the development and use of TCM for various health problems. And TCM has its advantages over chemical drugs through promoting wellness and prevention of diseases and fewer side effects. This favorable environment creates huge opportunity for Bohai in our view.
Bohai’s product portfolio targets a wide range of disease categories such as respiratory disease, rheumatoid arthritis, digestive disorders, and women’s health. Collectively, these disease categories represent a huge market for the Company.
Bohai has many advantages over its competitors. On top of that is the patented or “protected” status for its top products for exclusive or near-exclusive marketing rights. Also important are the insurance coverage of a large percentage of its products including its key products, low R&D costs, strong distribution network and pricing power.
We have an Outperform rating on Bohai’s shares with a price target of $7. We think current valuation is low, which does not reflect the Company’s strong fundamentals. We believe Bohai is well positioned to grow its business in a unique way and are poised to deliver shareholder value in the coming years.
For a free copy of the research report, please email scr@zacks.com with BOPH as the subject.
http://www.zacks.com/stock/news/52477/Why+should+investors+pay+attention+to+Bohai%3F
BOPH: Initiating coverage with Outperform rating
Zack's Investment Research
By: Arunima Bhowmick
April 16, 2011
BOPH
Grant Zeng, CFA
We are initiating coverage of Bohai Pharmaceuticals Group Inc. (BOPH - Analyst Report) with an Outperform rating. Our price target is $7.00 per share. Our call is based on the strong fundamentals of the Company.
Bohai is a well established specialty pharmaceutical company in China engaged in the production and commercialization of traditional Chinese medicine (TCM). The Company is operating in a favorable environment for the pharmaceutical, especially TCM, industry in China. China’s GDP will continue to grow at about 8% in the coming decade. Government spending in healthcare will also increase dramatically. The goal to achieve a universal health insurance is on track with at least 90% of population is covered by 2011. Government supports the development and use of TCM for various health problems. And TCM has its advantages over chemical drugs through promoting wellness and prevention of diseases and fewer side effects. This favorable environment creates huge opportunity for Bohai in our view.
Bohai’s product portfolio targets a wide range of disease categories such as respiratory disease, rheumatoid arthritis, digestive disorders, and women’s health. Collectively, these disease categories represent a huge market for the Company.
Bohai has many advantages over its competitors. On top of that is the patented or “protected” status for its top products for exclusive or near-exclusive marketing rights. Also important are the insurance coverage of a large percentage of its products including its key products, low R&D costs, strong distribution network and pricing power.
Bohai has a practical and appropriate growth strategy for both near term and long term growth. This strategy, combined with experienced management, will provide sustainable growth in the years to come for the Company.
Financial performance has been strong and is expected to continue to do well in the next few years. Both top line and bottom line will grow amazingly at about 27% and 15% respectively in the next 5 years. Earnings per share will increase to $0.90 per share on total revenue of $199 million in fiscal 2015.
Current valuation is low, which does not reflect the Company’s strong fundamentals. We believe Bohai is well positioned to grow its business in a unique way and are poised to deliver shareholder value in the coming years. Current valuation presents an opportunity for investors, who want to diversify their portfolio geographically and share China’s great economic success.
For a free copy of the full research report, please email scr@zacks.com with BOPH as the subject.
http://www.zacks.com/stock/news/51393/BOPH%3A++Initiating+coverage+with+Outperform+rating
The wildebeests come charging through here now and then but they never stay long. lol
Are they battery powered? lol eom
A 500 share trade? Doesn't seem realistic. eom
Power Technology is not a battery company anymore. They've been defunct as a battery entity for years. I would suggest working on DD a little bit better. Least someone thinks you are misleading.
It's a shame that PT's management always sucked. The "porosity" concept and advantages in batteries has become well established.
PT could have had a good thing going if not for management's greed and stupidity.
New carbon 'sponge' could revolutionize energy storage
By Chris Jablonski | May 12, 2011 ZDNet
Researchers at University of Texas - Austin have created a novel form of three-dimensional carbon that can be used as a greatly enhanced supercapacitor, holding promise for energy storage in everything from energy grids and electric cars to consumer electronics.
Credit: U.S. Department of Energy - Brookhaven National Laboratory
The new porous material has the potential to give supercapacitors a boost by delivering significantly more charge, opening the doors to many potential unprecedented uses for this type of electrical energy storage device, say the researchers.
“We synthesized a new sponge-like carbon that has a surface area of up to 3,100 square meters per gram (two grams has a surface area roughly equivalent to that of a football field). It also has much higher electrical conductivity and, when further optimized, will be superb for thermal management as well,” said University of Texas team leader Rodney Ruoff. “The processes used to make this porous carbon are readily scalable to industrial levels.”
Supercapacitors are similar to batteries in that both store electric charge, but batteries do so through chemical reactions that take time to react, which means energy is stored and released relatively slowly. Supercapacitors, on the other hand, store a charge in a way that is similar to static electricity and are able to deliver energy much faster and more efficiently than batteries, but usually hold much less electrical charge.
The new carbon material developed by the UT-Austin researchers may change that. Supercapacitors made from it have an energy-storage capacity that is approaching that of lead-acid batteries, while retaining the high power density characteristic of supercapacitors.
“This new material combines the attributes of both electrical storage systems,” said Ruoff. “After we realized that we had a new carbon with a highly novel structure that showed superb performance as an electrode, we knew that this direction of research — to create carbon materials that consist of a continuous three-dimensional porous network with single-atom-thick walls — was likely to yield the optimum electrode material for supercapacitors.” The widths of the pores range from 1 to 5 nanometers, or billionths of a meter.
To synthesize the carbon material, the team used microwaves to first exfoliate graphite oxide and then they treated it with potassium hydroxide, which created a carbon full of tiny holes — essentially a sponge that, when combined with an electrolyte, can store a giant electrical charge.
The next step was to confirm the precise shape of the material. Ruoff turned to scientists at the U.S. Department of Energy’s Brookhaven National Laboratory for a look at its nanoscale structure using the highest resolution microscopes in the world. Their observations confirmed Ruoff’s hypothesis that the carbon was a new three-dimensional material having highly curved, single-atom-thick walls of of crystalline carbon that form tiny pores (as seen in the above image).
Sources:
Cockrell School of Engineering
Brookhaven National Laboratory
Sounds a bit like PWTC's technology ...
Batteries Charge Quickly and Retain Capacity, Thanks to New Structure
ScienceDaily (Mar. 21, 2011) — The batteries in Illinois professor Paul Braun's lab look like any others, but they pack a surprise inside.
Braun's group developed a three-dimensional nanostructure for battery cathodes that allows for dramatically faster charging and discharging without sacrificing energy storage capacity. The researchers' findings will be published in the March 20 advance online edition of the journal Nature Nanotechnology.
Aside from quick-charge consumer electronics, batteries that can store a lot of energy, release it fast and recharge quickly are desirable for electric vehicles, medical devices, lasers and military applications.
"This system that we have gives you capacitor-like power with battery-like energy," said Braun, a professor of materials science and engineering. "Most capacitors store very little energy. They can release it very fast, but they can't hold much. Most batteries store a reasonably large amount of energy, but they can't provide or receive energy rapidly. This does both."
The performance of typical lithium-ion (Li-ion) or nickel metal hydride (NiMH) rechargeable batteries degrades significantly when they are rapidly charged or discharged. Making the active material in the battery a thin film allows for very fast charging and discharging, but reduces the capacity to nearly zero because the active material lacks volume to store energy.
Braun's group wraps a thin film into three-dimensional structure, achieving both high active volume (high capacity) and large current. They have demonstrated battery electrodes that can charge or discharge in a few seconds, 10 to 100 times faster than equivalent bulk electrodes, yet can perform normally in existing devices.
This kind of performance could lead to phones that charge in seconds or laptops that charge in minutes, as well as high-power lasers and defibrillators that don't need time to power up before or between pulses.
Braun is particularly optimistic for the batteries' potential in electric vehicles. Battery life and recharging time are major limitations of electric vehicles. Long-distance road trips can be their own form of start-and-stop driving if the battery only lasts for 100 miles and then requires an hour to recharge.
"If you had the ability to charge rapidly, instead of taking hours to charge the vehicle you could potentially have vehicles that would charge in similar times as needed to refuel a car with gasoline," Braun said. "If you had five-minute charge capability, you would think of this the same way you do an internal combustion engine. You would just pull up to a charging station and fill up."
All of the processes the group used are also used at large scales in industry so the technique could be scaled up for manufacturing.
They key to the group's novel 3-D structure is self-assembly. They begin by coating a surface with tiny spheres, packing them tightly together to form a lattice. Trying to create such a uniform lattice by other means is time-consuming and impractical, but the inexpensive spheres settle into place automatically.
Then the researchers fill the space between and around the spheres with metal. The spheres are melted or dissolved, leaving a porous 3-D metal scaffolding, like a sponge. Next, a process called electropolishing uniformly etches away the surface of the scaffold to enlarge the pores and make an open framework. Finally, the researchers coat the frame with a thin film of the active material.
The result is a bicontinuous electrode structure with small interconnects, so the lithium ions can move rapidly; a thin-film active material, so the diffusion kinetics are rapid; and a metal framework with good electrical conductivity.
The group demonstrated both NiMH and Li-ion batteries, but the structure is general, so any battery material that can be deposited on the metal frame could be used.
"We like that it's very universal, so if someone comes up with a better battery chemistry, this concept applies," said Braun, who is also affiliated with the Materials Research Laboratory and the Beckman Institute for Advanced Science and Technology at Illinois. "This is not linked to one very specific kind of battery, but rather it's a new paradigm in thinking about a battery in three dimensions for enhancing properties."
The U.S. Army Research Laboratory and the Department of Energy supported this work. Visiting scholar Huigang Zhang and former graduate student Xindi Yu were co-authors of the paper.
Email or share this story:
| More
Story Source:
The above story is reprinted (with editorial adaptations by ScienceDaily staff) from materials provided by University of Illinois at Urbana-Champaign.
Journal Reference:
1. Huigang Zhang, Xindi Yu, Paul V. Braun. Three-dimensional bicontinuous ultrafast-charge and -discharge bulk battery electrodes. Nature Nanotechnology, 2011; DOI: 10.1038/nnano.2011.38
PWTC is not in business. The last CEO (Walter), just like the first, was an idiot and pissed everything away including the patents. The only reason this thing still trades is due to confusion with other companies named Power Technology.
I'm so sorry for your loss Jeff. It hurts me to think how your mom must feel. Thank God we have the resurrection hope.
Don
I hope he shares a cell with Madoff. eom
I concur. eom
Any idea why? eom
There is nothing going on with PWTC. It's a puzzle as to why it still trades. The only thing that is left is the rotten stench from the two former idiot CEO's.
Those two numb nuts don't need any pain meds because no brain = no pain. Of course I was just as stupid for trusting in those two pieces of swine excrements.